Found: 17
Select item for more details and to access through your institution.
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 608, doi. 10.1007/s10637-017-0441-4
- By:
- Publication type:
- Article
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 599, doi. 10.1007/s10637-017-0433-4
- By:
- Publication type:
- Article
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 616, doi. 10.1007/s10637-017-0442-3
- By:
- Publication type:
- Article
Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 545, doi. 10.1007/s10637-017-0465-9
- By:
- Publication type:
- Article
Resistance to immunotherapy: clouds in a bright sky.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 649, doi. 10.1007/s10637-017-0456-x
- By:
- Publication type:
- Article
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 576, doi. 10.1007/s10637-017-0459-7
- By:
- Publication type:
- Article
New doxorubicin nanocarriers based on cyclodextrins.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 539, doi. 10.1007/s10637-017-0461-0
- By:
- Publication type:
- Article
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 627, doi. 10.1007/s10637-017-0444-1
- By:
- Publication type:
- Article
Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 665, doi. 10.1007/s10637-017-0469-5
- By:
- Publication type:
- Article
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 556, doi. 10.1007/s10637-017-0470-z
- By:
- Publication type:
- Article
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 634, doi. 10.1007/s10637-017-0473-9
- By:
- Publication type:
- Article
Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 662, doi. 10.1007/s10637-017-0462-z
- By:
- Publication type:
- Article
Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 566, doi. 10.1007/s10637-017-0477-5
- By:
- Publication type:
- Article
Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 642, doi. 10.1007/s10637-017-0482-8
- By:
- Publication type:
- Article
Pharmacokinetics and excretion of C-Plitidepsin in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 589, doi. 10.1007/s10637-017-0432-5
- By:
- Publication type:
- Article
Gankyrin as a potential therapeutic target for cancer.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 655, doi. 10.1007/s10637-017-0474-8
- By:
- Publication type:
- Article
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- Erratum